Literature DB >> 18220316

Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions.

As Savchenko1, M Imamura, R Ohashi, S Jiang, T Kawasaki, G Hasegawa, I Emura, H Iwanari, M Sagara, T Tanaka, T Hamakubo, T Kodama, M Naito.   

Abstract

Pentraxin 3 (PTX3) and C-reactive protein (CRP) are members of the pentraxin superfamily. PTX3 expression is induced in response to inflammatory signals, and is produced at sites of inflammation by several types of cell, primarily monocytes/macrophages, dendritic cells (DCs), endothelial cells, smooth muscle cells (SMCs), and fibroblasts, but is not produced by hepatocytes, which are a major source of CRP. The aim of our study was to investigate the expression pattern of PTX3 in human atherosclerotic lesions using a novel monoclonal antibody against PTX3. We examined coronary arterial thrombi containing an atherosclerotic plaque component removed from patients with acute myocardial infarction and human aortic tissues with various degrees of atherosclerosis sampled from autopsy cases. Immunohistochemical study of paraffin and frozen sections indicated that macrophages, mainly foam cells, expressed PTX3 in advanced atherosclerotic lesions. Interestingly, we also clearly observed PTX3-positive neutrophils infiltrating into atherosclerotic plaques, suggesting that PTX3 derived from neutrophils as well as macrophages plays an important role in atherogenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18220316     DOI: 10.1002/path.2314

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  58 in total

1.  Differential associations of serum amyloid A and pentraxin-3 with allele-specific lipoprotein(a) levels in African Americans and Caucasians.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Zeynep Ozturk; Wei Zhang; Thomas A Pearson; Lars Berglund
Journal:  Transl Res       Date:  2011-02-05       Impact factor: 7.012

Review 2.  Human neutrophil peptides: a novel potential mediator of inflammatory cardiovascular diseases.

Authors:  Kieran Quinn; Melanie Henriques; Tom Parker; Arthur S Slutsky; Haibo Zhang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-09-19       Impact factor: 4.733

3.  Combined therapy with renin-angiotensin system and calcium channel blockers in type 2 diabetic hypertensive patients with proteinuria: effects on soluble TWEAK, PTX3, and flow-mediated dilation.

Authors:  Mahmut Ilker Yilmaz; Juan Jesús Carrero; Jose Luis Martín-Ventura; Alper Sonmez; Mutlu Saglam; Turgay Celik; Halil Yaman; Mujdat Yenicesu; Tayfun Eyileten; Juan Antonio Moreno; Jesús Egido; Luis Miguel Blanco-Colio
Journal:  Clin J Am Soc Nephrol       Date:  2010-04-29       Impact factor: 8.237

Review 4.  Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target.

Authors:  N Glezeva; J A Baugh
Journal:  Heart Fail Rev       Date:  2014-09       Impact factor: 4.214

5.  Inflammatory response to percutaneous coronary intervention in stable coronary artery disease.

Authors:  Peter S Munk; Unni M Breland; Pål Aukrust; Oyvind Skadberg; Thor Ueland; Alf I Larsen
Journal:  J Thromb Thrombolysis       Date:  2011-01       Impact factor: 2.300

6.  Relationship between Plasma Pentraxin-3, Neutrophil-to-Lymphocyte Ratio, and Atherosclerosis in Renal Transplant Patients.

Authors:  Kultigin Turkmen; Fatih Mehmet Erdur; Ibrahim Guney; Huseyin Ozbiner; Aysun Toker; Abduzhappar Gaipov; Orhan Ozbek; Mehdi Yeksan; Halil Zeki Tonbul; Suleyman Turk
Journal:  Cardiorenal Med       Date:  2012-11-16       Impact factor: 2.041

7.  Effect of renin angiotensin system blockade on pentraxin 3 levels in type-2 diabetic patients with proteinuria.

Authors:  Mahmut Ilker Yilmaz; Jonas Axelsson; Alper Sonmez; Juan Jesus Carrero; Mutlu Saglam; Tayfun Eyileten; Kayser Caglar; Alper Kirkpantur; Turgay Celik; Yusuf Oguz; Abdulgaffar Vural; Mujdat Yenicesu; Bengt Lindholm; Peter Stenvinkel
Journal:  Clin J Am Soc Nephrol       Date:  2009-02-11       Impact factor: 8.237

Review 8.  Biology of human pentraxin 3 (PTX3) in acute and chronic kidney disease.

Authors:  Marijn M Speeckaert; Reinhart Speeckaert; Juan J Carrero; Raymond Vanholder; Joris R Delanghe
Journal:  J Clin Immunol       Date:  2013-02-27       Impact factor: 8.317

9.  Pentraxin-3 and the right ventricle: the Multi-Ethnic Study of Atherosclerosis-Right Ventricle Study.

Authors:  Peter J Leary; Nancy S Jenny; R Graham Barr; David A Bluemke; Michael O Harhay; Susan R Heckbert; Richard A Kronmal; João A Lima; Carmen Mikacenic; Russell P Tracy; Steven M Kawut
Journal:  Pulm Circ       Date:  2014-06       Impact factor: 3.017

10.  Characterization of pentraxin 3 in the horse and its expression in airways.

Authors:  Eve Ramery; Laurence Fievez; Audrey Fraipont; Fabrice Bureau; Pierre Lekeux
Journal:  Vet Res       Date:  2009-10-29       Impact factor: 3.683

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.